3-rx.comCustomer Support
3-rx.com
   
HomeAbout UsFAQContactHelp
News Center
Health Centers
Medical Encyclopedia
Drugs & Medications
Diseases & Conditions
Medical Symptoms
Med. Tests & Exams
Surgery & Procedures
Injuries & Wounds
Diet & Nutrition
Special Topics



\"$alt_text\"');"); } else { echo"\"$alt_text\""; } ?>


Join our Mailing List





Syndicate

You are here : 3-RX.com > Home > Drug News - Heart -

Aspirin reduces death rate in heart patients

Drug News • • HeartJan 29, 08

In people with stable heart disease, low-dose aspirin reduces the occurrence of heart attacks, strokes, and deaths from all causes, according to a new analysis.

Although aspirin also increases the risk of bleeding, the benefits outweigh the risk, lead author Dr. Jeffrey S. Berger, of the Duke Clinical Research Institute, Durham, North Carolina, and his associates conclude in their report in the American Journal of Medicine.

Unlike previous analyses that combined various populations with treated with different blood-thinning drugs and dosages, the researchers point out, “our study focuses on low-dose aspirin in a population with stable cardiovascular disease.”

Berger’s group identified six clinical trials that included nearly 10,000 patients with stable heart-related chest pain or a history of heart attack, stroke, or mini-stroke.

Compared to inactive placebo treatment, aspirin therapy was associated with a 13 percent reduction in the odds of dying during follow-up, a 26 percent reduction in the odds of a non-fatal heart attack, and a 25 percent reduction in the odds of stroke.

In a subgroup analysis, low doses of aspirin (50 to 100 milligrams per day) were shown to be as effective as a higher dose (300 milligrams per day).

Although long-term aspirin therapy doubled the risk of major bleeding, Berger’s group notes that the absolute risk was still low.

They calculate that among 1000 patients, low-dose aspirin would prevent approximately 33 heart attacks or stroke and 14 deaths, and cause approximately 9 episodes of serious bleeding—a worthwhile trade-off.

SOURCE: American Journal of Medicine, January 2008.



Print Version
Tell-a-Friend
comments powered by Disqus

RELATED ARTICLES:
  New biomarkers may influence drug design and alternative treatments of cancer, study shows
  UGA ecologist finds another cause of antibiotic resistance
  New drug for neuroblastoma shows promise in phase I study
  Baclofen shows promise in patients with alcohol-induced liver disease
  Findings point to an ‘off switch’ for drug resistance in cancer
  New superfoods could help key protein keep bodies healthy
  Mobile app on emergency cardiac care aids best decisions in seconds
  Train your heart to protect your mind
  Stopping statins may benefit terminally ill patients
  Cholesterol drug users may use pills as a license to overeat
  Pfizer lung cancer drug beats chemo for previously untreated patients
  Mass. General study identifies path to safer drugs for heart disease, cancer

 












Home | About Us | FAQ | Contact | Advertising Policy | Privacy Policy | Bookmark Site